TY - JOUR T1 - RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES JO - Value in Health PY - 2019/05/01 AU - Li N AU - Bullement A AU - McMordie S AU - Hatswell AJ AU - Wilson K ED - DO - DOI: 10.1016/j.jval.2019.04.1898 PB - Elsevier BV VL - 22 SP - S389 EP - S389 Y2 - 2025/05/17 ER -